X4 Pharmaceuticals (NASDAQ:XFOR) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR - Free Report) in a report issued on Tuesday morning,Benzinga reports. They currently have a $1.50 price objective on the stock.

Separately, Stifel Nicolaus reduced their price objective on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Thursday, November 14th.

X4 Pharmaceuticals Stock Down 19.4 %

X4 Pharmaceuticals stock traded down $0.11 during trading on Tuesday, reaching $0.46. The stock had a trading volume of 3,830,999 shares, compared to its average volume of 3,286,737. The stock has a market cap of $77.73 million, a PE ratio of -5.06 and a beta of 0.14. The business has a 50 day moving average price of $0.55 and a 200 day moving average price of $0.61. X4 Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $1.60. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP acquired a new stake in shares of X4 Pharmaceuticals in the third quarter valued at about $340,000. K2 Principal Fund L.P. purchased a new position in shares of X4 Pharmaceuticals during the second quarter valued at approximately $284,000. AQR Capital Management LLC raised its stake in X4 Pharmaceuticals by 1,080.3% during the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company's stock worth $246,000 after purchasing an additional 388,115 shares during the period. State Street Corp lifted its stake in shares of X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company's stock valued at $1,976,000 after purchasing an additional 189,105 shares in the last quarter. Finally, Barclays PLC increased its position in shares of X4 Pharmaceuticals by 196.0% in the third quarter. Barclays PLC now owns 277,682 shares of the company's stock worth $185,000 after acquiring an additional 183,861 shares in the last quarter. Institutional investors and hedge funds own 72.03% of the company's stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.